Not Signed In -
Aripiprazole |
Abilify |
Clinical Trial: Study of Three Doses of Aripiprazole in Patients with Acute Schizophrenia
This study is no longer recruiting patients.
|
Purpose
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Schizophrenia | Drug: aripiprazole (Abilify TM) | Phase IV |
MedlinePlus related topics: Schizophrenia
Study Type: Interventional
Study Design: Treatment
Official Title: A Placebo-Controlled Study of Three Doses of Aripiprazole in Patients with Acute Schizophrenia
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Men and women, ages 18 and older, with a worsening of schizophrenia sysmptoms over the past three months
Location Information
Connecticut
Bristol-Meyers Squibb Call Center, Wallingford, Connecticut, United States
More Information
Study ID Numbers: CN138-113 ST
Record last reviewed: August 2004
Last Updated: October 13, 2004
Record first received: March 26, 2004
ClinicalTrials.gov Identifier: NCT00080327
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: August 2004
Last Updated: October 13, 2004
Record first received: March 26, 2004
ClinicalTrials.gov Identifier: NCT00080327
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
email this page
print this page
bookmark this page
feedback on this page
